多药丸和组合疗法:降低血压和心血管风险
Jinwook Park1, Chien-Wen Yang2, Yonghong Huan3
1Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA. Jinwook.park@louisville.edu.
Current cardiology reports
|November 22, 2023
概括
固定剂量组合药丸,包括用药品3D打印制成的药丸,可以改善血压控制和血压坚持. 这些组合疗法为预防心血管疾病提供了较低的药丸负担.
科学领域:
- 制药科学 制药科学
- 心脏病学 心脏病学
- 医疗技术 医疗技术 医学技术
背景情况:
- 越来越多的多药,特别是心脏保护药物,在患者遵守和管理方面带来了挑战.
- 固定剂量组合 (FDC) 药物提供了一种减少药片负担的策略.
- 制药3D打印技术可以创建单片药片,其中包含多种药物和各种释放配置.
研究的目的:
- 审查支持使用组合药丸治疗心血管疾病的证据.
- 探索制药3D打印在开发先进的FDC疗法的作用.
- 评估FDC对血压控制和患者遵守法规的影响.
主要方法:
- 关于FDC药物的最近随机对照试验和研究的审查.
- 检查新兴的制药3D打印技术 (例如,基于粉末的,化沉积模型,半固体挤出).
- 对血压控制率,坚持和与FDC治疗相关的不良事件数据的分析.
主要成果:
- 最近的研究表明,使用四药治疗方案与单一治疗相比,血压控制率更高.
- 与常规护理相比,低剂量三倍FDC改善了6个月的血压控制.
- 支持FDC治疗以预防初级和二级心血管疾病,但不显著增加不良事件.
- 制药3D打印为临床FDC利用提供了灵活性,可负担性和可行性.
结论:
- 固定剂量组合疗法有效降低了药丸负担,可能提高了心血管疾病管理的坚持和有效性.
- 制药3D打印是一种有前途的技术,用于创建定制的FDC药物.
- 需要多学科的方法和进一步的研究来优化FDC治疗和初始的抗高血压治疗策略.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
534
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
534
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
672
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
672
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
176
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
176
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K